Izba

1 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ANNEX I 

 

SUMMARY OF PRODUCT CHARACTERISTICS 



 

2 

1. NAME OF THE MEDICINAL PRODUCT 

 

IZBA 30 micrograms/mL eye drops, solution 

 

 

2. QUALITATIVE AND QUANTITATIVE COMPOSITION 

 

One mL of solution contains 30 micrograms of travoprost. 

 

Excipients with known effect 

 

One mL of solution contains 7.5 mg propylene glycol and 2 mg polyoxyethylene hydrogenated castor 

oil 40 (HCO-40) (see section 4.4). 

 

For the full list of excipients, see section 6.1. 

 

 

3. PHARMACEUTICAL FORM 

 

Eye drops, solution (eye drops). 

 

Clear, colourless solution. 

 

 

4. CLINICAL PARTICULARS 

 

4.1 Therapeutic indications 

 

Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle 

glaucoma (see section 5.1). 

 

Decrease of elevated intraocular pressure in paediatric patients aged 3 years to <18 years with ocular 

hypertension or paediatric glaucoma (see section 5.1). 

 

4.2 Posology and method of administration 

 

Posology 

 

Use in adults, including elderly patients 

The dose is one drop of travoprost in the conjunctival sac of the affected eye(s) once daily. Optimal 

effect is obtained if the dose is administered in the evening. 

 

Nasolacrimal occlusion or gently closing the eyelid after administration is recommended. This may 

reduce the systemic absorption of medicinal products administered via the ocular route and result in a 

decrease in systemic adverse reactions. 

 

If more than one topical ophthalmic medicinal product is being used, the medicinal products must be 

administered at least 5 minutes apart. 

 

If a dose is missed, treatment should be continued with the next dose as planned. The dose should not 

exceed one drop in the affected eye(s) daily. 

 

When substituting another ophthalmic antiglaucoma medicinal product with IZBA, the other 

medicinal product should be discontinued and IZBA should be started the following day. 



 

3 

 

Hepatic and renal impairment 

Travoprost 30 µg/mL has not been studied in patients with hepatic or renal impairment. However, 

travoprost 40 µg/mL has been studied in patients with mild to severe hepatic impairment and in 

patients with mild to severe renal impairment (creatinine clearance as low as 14 mL/min). No dosage 

adjustment is necessary in these patients (see section 5.2). Therefore, no need for dose adjustment at 

the lower concentration of active ingredient is anticipated. 

 

Paediatric population 

IZBA can be used in paediatric patients from 3 years to <18 years at the same posology as in adults 

(see section 5.1). 

 

The safety and efficacy of IZBA in children below the age of 3 years have not been established. 

Currently available data are described in section 5.1 but no recommendation on a posology below the 

age of 3 years can be made. 

 

Method of administration 

 

For ocular use. 

 

For patients who wear contact lenses, please refer to section 4.4. 

 

The patient should remove the protective overwrap immediately prior to initial use. To prevent 

contamination of the dropper tip and solution, care must be taken not to touch the eyelids, surrounding 

areas or other surfaces with the dropper tip of the bottle. 

 

4.3 Contraindications 

 

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 

 

4.4 Special warnings and precautions for use 

 

Eye colour change 

 

IZBA may gradually change the eye colour by increasing the number of melanosomes (pigment 

granules) in melanocytes. Before treatment is instituted, patients must be informed of the possibility of 

a permanent change in eye colour. Unilateral treatment can result in permanent heterochromia. The 

long-term effects on the melanocytes and any consequences thereof are currently unknown. The 

change in iris colour occurs slowly and may not be noticeable for months to years. The change in eye 

colour has predominantly been seen in patients with mixed coloured irides, i.e., blue-brown, 

grey-brown, yellow-brown and green-brown; however, it has also been observed in patients with 

brown eyes. Typically, the brown pigmentation around the pupil spreads concentrically towards the 

periphery in affected eyes, but the entire iris or parts of it may become more brownish. After 

discontinuation of therapy, no further increase in brown iris pigment has been observed. 

 

Periorbital and eye lid changes 

 

In controlled clinical trials, periorbital and/or eyelid skin darkening in association with the use of 

IZBA has been reported in 0.2% of patients. 

 

Periorbital and lid changes including deepening of the eyelid sulcus have been observed with 

prostaglandin analogues. 

 

IZBA may gradually change eyelashes in the treated eye(s); these changes were observed in about half 

of the patients in clinical trials and include: increased length, thickness, pigmentation, and/or number 

of lashes. The mechanism of eyelash changes and their long-term consequences are currently 

unknown. 



 

4 

 

There is no experience of IZBA in inflammatory ocular conditions; nor in neovascular, angle-closure, 

narrow-angle or congenital glaucoma and only limited experience in thyroid eye disease, in 

open-angle glaucoma of pseudophakic patients and in pigmentary or pseudoexfoliative glaucoma. 

IZBA should therefore be used with caution in patients with active intraocular inflammation. 

 

Aphakic patients 

 

Macular oedema has been reported during treatment with prostaglandin F2a analogues. Caution is 

recommended when using IZBA in aphakic patients, pseudophakic patients with a torn posterior lens 

capsule or anterior chamber lenses, or in patients with known risk factors for cystoid macular oedema. 

 

Iritis/uveitis 

 

In patients with known predisposing risk factors for iritis/uveitis, IZBA should be used with caution. 

 

Contact with the skin 

 

Skin contact with IZBA must be avoided as transdermal absorption of travoprost has been 

demonstrated in rabbits. 

 

Prostaglandins and prostaglandin analogues are biologically active materials that may be absorbed 

through the skin. Women who are pregnant or attempting to become pregnant should exercise 

appropriate precautions to avoid direct exposure to the contents of the bottle. In the unlikely event of 

coming in contact with a substantial portion of the contents of the bottle, thoroughly cleanse the 

exposed area immediately. 

 

Contact lenses 

 

Patients must be instructed to remove contact lenses prior to application of IZBA and wait 15 minutes 

after instillation of the dose before reinsertion. 

 

Excipients 

 

IZBA contains propylene glycol which may cause skin irritation. 

IZBA contains polyoxyethylene hydrogenated castor oil 40 which may cause skin reactions. 

 

Paediatric population 

 

No long-term safety data are available in the paediatric population. 

 

4.5 Interaction with other medicinal products and other forms of interaction 

 

No interaction studies have been performed. 

 

4.6 Fertility, pregnancy and lactation 

 

Women of childbearing potential/contraception 

 

Travoprost must not be used in women of childbearing age/potential unless adequate contraceptive 

measures are in place (see section 5.3). 

 

Pregnancy 

 

Travoprost has harmful pharmacological effects on pregnancy and/or the foetus/new-born child. 

Travoprost should not be used during pregnancy unless clearly necessary. 

 



 

5 

Breast-feeding 

 

It is unknown whether travoprost from eye drops is excreted in human breast milk. Animal studies 

have shown excretion of travoprost and metabolites in breast milk. The use of travoprost by 

breast-feeding mothers is not recommended. 

 

Fertility 

 

There are no data on the effects of travoprost on human fertility. Animal studies showed no effect of 

travoprost on fertility at doses more than 250 times the maximum recommended human ocular dose. 

 

4.7 Effects on ability to drive and use machines 

 

IZBA has no or negligible influence on the ability to drive and use machines. 

Temporary blurred vision or other visual disturbances may affect the ability to drive or use machines. 

If blurred vision occurs at instillation, the patient must wait until the vision clears before driving or 

using machines. 

 

4.8 Undesirable effects 

 

Summary of the safety profile 

 

In a clinical trial of 3 months duration (N=442) involving IZBA as monotherapy, the most common 

adverse reaction observed was hyperaemia of the eye (ocular or conjunctival) reported in 

approximately 12% of the patients. 

 

Tabulated list of adverse reactions 

 

The following adverse reactions were assessed to be related with IZBA monotherapy and are 

classified according to the following convention: very common (≥1/10), common (≥1/100 to 

<1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000) and very rare 

(<1/10,000). Within each frequency grouping in Table 1, adverse reactions are presented in 

decreasing order of seriousness. 

 

Table 1 Travoprost 30 µg/mL eye drops, solution 

 

System Organ class Frequency Adverse reaction 

Eye disorders Very common ocular hyperaemia  

Common dry eye, eye pruritus, ocular discomfort 

Uncommon punctate keratitis, anterior chamber 

inflammation, blepharitis, eye pain, 

photophobia, visual impairment, vision blurred, 

conjunctivitis, eyelid oedema, eyelid margin 

crusting, eye discharge, dark circles under 

eyes, growth of eyelashes, eyelash thickening 

Skin and subcutaneous 

tissue disorders 

Uncommon pruritus, rash 

 

The following adverse reactions were assessed to be related with travoprost 40 µg/mL eye drops, 

solution (either benzalkonium chloride [BAK] or Polyquad-preserved) and are classified according to 
the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to 

<1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000) and not known (cannot be estimated from 

the available data). Within each frequency grouping in Table 2, adverse reactions are presented in 

decreasing order of seriousness. 

 



 

6 

Table 2 Travoprost 40 µg/mL eye drops, solution 

 

System Organ class Frequency Adverse reaction 

Immune system disorders Uncommon hypersensitivity, seasonal allergy 

Psychiatric disorders Not known depression, anxiety, insomnia 

Nervous system disorders Uncommon headache 

Rare dysgeusia, dizziness, visual field defect 

Eye disorders Very common ocular hyperaemia 

Common iris hyperpigmentation, eye pain, ocular 

discomfort, dry eye, eye pruritus, eye irritation 

Uncommon corneal erosion, uveitis, iritis, anterior chamber 

inflammation, keratitis, punctate keratitis, 

photophobia, eye discharge, blepharitis, 

erythema of eyelid, periorbital oedema, eyelids 

pruritus, visual acuity reduced, vision blurred, 

lacrimation increased, conjunctivitis, ectropion, 

cataract, eyelid margin crusting, growth of 

eyelashes 

Rare iridocyclitis, ophthalmic herpes simplex, eye 

inflammation, photopsia, eczema eyelids, 

conjunctival oedema, halo vision, conjunctival 

follicles, hypoaesthesia eye, trichiasis 

meibomianitis, anterior chamber pigmentation, 

mydriasis, asthenopia, eyelash 

hyperpigmentation, eyelash thickening 

Not known macular oedema, lid sulcus deepened 

Ear and labyrinth disorders Not known vertigo, tinnitus 

Cardiac disorders Uncommon palpitations 

Rare heart rate irregular, heart rate decreased 

Not known chest pain, bradycardia, tachycardia, arrhythmia 

Vascular disorders Rare blood pressure diastolic decreased, blood 

pressure systolic increased, hypotension, 

hypertension 

Respiratory, thoracic and 

mediastinal disorders 

Uncommon cough, nasal congestion, throat irritation 

Rare dyspnoea, asthma, respiratory disorder, 

oropharyngeal pain, dysphonia, rhinitis allergic, 

nasal dryness 

Not known asthma aggravated, epistaxis 

Gastrointestinal disorders Rare  peptic ulcer reactivated, dry mouth 

gastrointestinal disorder, constipation 

Not known diarrhoea, abdominal pain, nausea, vomiting 

Skin and subcutaneous tissue 

disorders 

Uncommon skin hyperpigmentation (periocular), skin 

discolouration, hair texture abnormal, 

hypertrichosis 

Rare dermatitis allergic, , dermatitis contact, 

erythema, rash, hair colour changes, madarosis 

Not known Pruritus, hair growth abnormal 

Musculoskeletal and connective 

tissue disorders 

Rare musculoskeletal pain, arthralgia 

Renal and urinary disorders Not known dysuria, urinary incontinence 

General disorders and 

administration site conditions  

Rare asthenia 

Investigations Not known prostatic specific antigen increased 

 



 

7 

Paediatric population 

 

In a 3-month phase 3 study and a 7-day pharmacokinetic study, involving 102 paediatric patients 

exposed to travoprost 40 micrograms/mL eye drops, solution, the types and characteristics of adverse 

reactions reported were similar to what has been observed in adult patients. The short-term safety 

profiles in the different paediatric subsets were also similar (see section 5.1). The most frequent 

adverse reactions reported in the paediatric population were ocular hyperaemia (16.9%) and growth of 

eyelashes (6.5%). In a similar 3-month study in adult patients, these events occurred at an incidence of 

11.4% and 0%, respectively. 

 

Additional adverse reactions reported in paediatric patients in the 3-month paediatric study (n=77) 

compared to a similar trial in adults (n=185) included erythema of eyelid, keratitis, lacrimation 

increased, and photophobia, all reported as single events with an incidence of 1.3% versus 0.0% seen 

in adults. 

 

Reporting of suspected adverse reactions 

 

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It 

allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare 

professionals are asked to report any suspected adverse reactions via the national reporting system 

listed in Appendix V. 

 

4.9 Overdose 

 

A topical overdose is not likely to occur or to be associated with toxicity. A topical overdose of 

travoprost may be flushed from the eye(s) with lukewarm water. Treatment of a suspected oral 

ingestion is symptomatic and supportive. 

 

 

5. PHARMACOLOGICAL PROPERTIES 

 

5.1 Pharmacodynamic properties 

 

Pharmacotherapeutic group: Ophthalmologicals, antiglaucoma preparations and miotics, ATC code: 

S01EE04 

 

Mechanism of action 

 

Travoprost, a prostaglandin F2 analogue, is a highly selective full agonist which has a high affinity for 

the prostaglandin FP receptor, and reduces the intraocular pressure by increasing the outflow of 

aqueous humour via trabecular meshwork and uveoscleral pathways. Reduction of the intraocular 

pressure in man starts about 2 hours after administration and maximum effect is reached after 

12 hours. Significant lowering of intraocular pressure can be maintained for periods exceeding 

24 hours with a single dose. 

 

Clinical efficacy and safety 

 

In a clinical trial, patients with open-angle glaucoma or ocular hypertension treated with IZBA dosed 

once-daily in the evening, demonstrated intraocular pressure lowering equivalent to travoprost 

40 µg/mL eye drops, solution at all on-therapy visits and time points (95% CI within ±1.0 mmHg). 

The mean reduction from baseline in IOP ranged from 7.1 to 8.2 mmHg as summarised in Table 3. 

The mean percent reductions in IOP from baseline to each study visit and assessment time point 

ranged from 28.4% to 30.7%. 

 

http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc


 

8 

Table 3 IOP change from baseline (mmHg) for IZBA 

 

Visit   8 AM 10 AM 4 PM 

Week 2 Mean -8.0 -7.3 -7.1 

(N=442) 95% CI (-8.3, -7.7) (-7.6, -7.0) (-7.4, -6.8) 

Week 6 Mean -8.1 -7.4 -7.2 

(N=440*) 95% CI (-8.4, -7.9) (-7.6, -7.1) (-7.5, -6.9) 

Month 3 Mean -8.2 -7.5 -7.1 

(N=432*) 95% CI (-8.6, -7.9) (-7.9, -7.2) (-7.4, -6.8) 

*One subject had missing data at 8 AM at Week 6; one had missing data at 4 PM at Month 3. 

 

An improved safety profile has been observed for IZBA when compared to the marketed travoprost 

40 µg/mL eye drops, solution (benzalkonium chloride preserved or polyquaternium-1 perserved). The 

most common adverse reaction associated with both IZBA and travoprost 40 µg/mL eye drops, 

solution is hyperaemia. Hyperaemia (ocular or conjunctival) was observed in 11.8% of patients 

(N=442) exposed to IZBA compared with 14.5% observed for patients exposed to travoprost 

40 µg/mL eye drops, solution, benzalkonium chloride preserved. 

 

Secondary pharmacology 

 

Travoprost significantly increased optic nerve head blood flow in rabbits following 7 days of topical 

ocular administration (1.4 micrograms, once-daily). 

 

Travoprost 40 µg/mL eye drops, solution preserved with polyquaternium-1 induced minimal ocular 

surface toxicity, compared to eye drops preserved with benzalkonium chloride, on cultured human 

corneal cells and following topical ocular administration in rabbits. 

 

Paediatric population 

 

IZBA has not been specifically studied in a clinical trial involving paediatric subjects. However, a 

modelling approach demonstrated that IOP lowering would be expected to be equivalent in paediatric 

patients aged 3 years and above using both IZBA and TRAVATAN (travoprost 40 micrograms/mL 

eye drops, solution). The studies used in the model were two dose response trials, one Phase III study 

using IZBA and a paediatric study using TRAVATAN (travoprost 40 micrograms/mL eye drops, 

solution). 

 

The efficacy of TRAVATAN (travoprost 40 micrograms/mL eye drops, solution) in paediatric patients 

from 2 months to less than 18 years of age was demonstrated in a 12-week, double-masked clinical 

study of travoprost compared with timolol in 152 patients diagnosed with ocular hypertension or 

paediatric glaucoma. Patients received either travoprost 0.004% once daily or timolol 0.5% (or 0.25% 

for subjects younger than 3 years old) twice daily. The primary efficacy endpoint was the intraocular 

pressure (IOP) change from baseline at Week 12 of the study. Mean IOP reductions in the travoprost 

and timolol groups were similar (see Table 4). 

 

In the age groups 3 to <12 years (n=36) and 12 to <18 years (n=26), mean IOP reduction at Week 12 

in the travoprost group was similar to that in the timolol group. Mean IOP reduction at Week 12 in the 

2 months to <3 years of age group was 1.8 mmHg in the travoprost group and 7.3 mmHg in the 

timolol group. IOP reductions for this group were based on only 6 patients in the timolol group and 

9 patients in the travoprost group where 4 patients in the travoprost group versus 0 patients in the 

timolol group had no relevant mean IOP reduction at Week 12. No data are available for children less 

than 2 months old. 

 

The effect on IOP was seen after the second week of treatment and was consistently maintained 

throughout the 12 week period of study for all age groups. 

 



 

9 

Table 4 Comparison of Mean IOP Change from Baseline (mmHg) at Week 12 

 

 Travoprost Timolol   

 N 

Mean 

(SE) N 

Mean  

(SE) 

Mean 

Differencea (95% CI) 

 53 -6.4  

(1.05) 

60 -5.8  

(0.96) 

-0.5 (-2.1, 1.0) 

SE = Standard Error; CI = Confidence Interval; 
aMean difference is travoprost – timolol. Estimates based on least squares means derived from a 

statistical model that accounts for correlated IOP measurements within patient where primary 

diagnosis and baseline IOP stratum are in the model. 

 

5.2 Pharmacokinetic properties 

 

Absorption 

 

Travoprost is an ester prodrug. It is absorbed through the cornea where the isopropyl ester is 

hydrolysed to the active free acid. Studies in rabbits have shown peak concentrations of 20 ng/g of the 

free acid in aqueous humour one to two hours after topical dosing of travoprost 40 µg/mL eye drops, 

solution. Aqueous humour concentrations declined with a half-life of approximately 1.5 hours. 

 

Distribution 

 

Following topical ocular administration of travoprost 40 µg/mL eye drops, solution to healthy 

volunteers, low systemic exposure to active free acid was demonstrated. Peak active free acid plasma 

concentrations of 25 pg/mL or less were observed between 10 and 30 minutes post-dose. Thereafter, 

plasma levels declined rapidly to below the 10 pg/mL assay quantitation limit before 1 hour 

post-administration. Due to the low plasma concentrations and rapid elimination following topical 

dosing, the elimination half-life of active free acid in man could not be determined. 

 

Biotransformation 

 

Metabolism is the major route of elimination of both travoprost and the active free acid. The systemic 

metabolic pathways parallel those of endogenous prostaglandin F2 which are characterised by 

reduction of the double bond in position C13-C14, oxidation of the 15-hydroxyl and -oxidative 

cleavages of the upper side chain. 

 

Elimination 

 

Travoprost free acid and its metabolites are mainly excreted by the kidneys. Travoprost 40 µg/mL eye 

drops, solution has been studied in patients with mild to severe hepatic impairment and in patients 

with mild to severe renal impairment (creatinine clearance as low as 14 mL/min). No dosage 

adjustment is necessary in these patients. 

 

Paediatric population 

 

A pharmacokinetic study of TRAVATAN (travoprost 40 micrograms/mL eye drops, solution) in 

paediatric patients aged 2 months to <18 years demonstrated low plasma exposure to travoprost free 

acid, with concentrations ranging from below the 10 pg/mL assay limit of quantitation (BLQ) to 

54.5 pg/mL. 

 

5.3 Preclinical safety data 

 

In ocular toxicity studies in monkeys, administration of travoprost at a dose of 0.45 microgram, twice 

a day, was shown to induce increased palpebral fissure. Topical ocular administration of travoprost to 

monkeys at concentrations of up to 0.012% to the right eye, twice daily for one year resulted in no 

systemic toxicity. 



 

10 

 

Increased palpebral fissure observed in monkeys were not seen in rabbits or in the clinical trials with 

travoprost products and is considered to be species specific. 

 

Reproduction toxicity studies have been undertaken in rat, mice and rabbit by systemic route. Findings 

are related to FP receptor agonist activity in uterus with early embryolethality, post-implantation loss, 

foetotoxicity. In pregnant rat, systemic administration of travoprost at doses more than 200 times the 

clinical dose during the period of organogenesis resulted in an increased incidence of malformations. 

Low levels of radioactivity were measured in amniotic fluid and foetal tissues of pregnant rats 

administered 3H-travoprost. Reproduction and development studies have demonstrated a potent effect 

on foetal loss with a high rate observed in rats and mice (180 pg/mL and 30 pg/mL plasma, 

respectively) at exposures 1.2 to 6 times the clinical exposure (up to 25 pg/mL). 

 

Environmental Risk Assessment (ERA) 

 

Travoprost is considered a persistent, bioaccumulative and toxic (PBT) substance. Hence, despite the 

very small amounts of travoprost used by patients in eye drops, a risk to the environment cannot be 

excluded. 

 

 

6. PHARMACEUTICAL PARTICULARS 

 

6.1 List of excipients 

 

Polyquaternium-1 

Polyoxyethylene hydrogenated castor oil 40 (HCO-40) 

Boric acid (E284) 

Mannitol (E421) 

Sodium chloride 

Propylene glycol (E1520) 

Sodium hydroxide and/or hydrochloric acid (to adjust pH) 

Purified water 

 

6.2 Incompatibilities 

 

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal 

products. 

 

6.3 Shelf life 

 

2 years. 

 

Discard 4 weeks after first opening. 

 

6.4 Special precautions for storage 

 

This medicinal product does not require any special storage conditions. 

 

6.5 Nature and contents of container 

 

IZBA is packaged in a 4 mL syndiotactic polypropylene (sPP) oval bottle with polypropylene (PP) 

dispensing plugs and closures presented in an overwrap. Each 4 mL bottle will contain 2.5 mL of 

solution. 

 

Cartons containing 1 or 3 bottles. 

 

Not all pack sizes may be marketed. 



 

11 

 

6.6 Special precautions for disposal 

 

Any unused medicinal product or waste material should be disposed of in accordance with local 

requirements. It should be noted that travoprost is considered a PBT substance (see section 5.3). 

 

 

7. MARKETING AUTHORISATION HOLDER 

 

Novartis Europharm Limited 

Vista Building 

Elm Park, Merrion Road 

Dublin 4 

Ireland 

 

 

8. MARKETING AUTHORISATION NUMBERS 

 

EU/1/13/905/001-002 

 

 

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 

 

Date of first authorisation: 20 February 2014 

Date of latest renewal: 

 

 

10. DATE OF REVISION OF THE TEXT 

 

 

Detailed information on this medicinal product is available on the website of the European Medicines 

Agency http://www.ema.europa.eu 

 

http://www.ema.europa.eu/


 

12 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ANNEX II 

 

A. MANUFACTURER(S) RESPONSIBLE FOR BATCH 

RELEASE 

 

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY 

AND USE 

 

C. OTHER CONDITIONS AND REQUIREMENTS OF THE 

MARKETING AUTHORISATION 

 

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO 

THE SAFE AND EFFECTIVE USE OF THE MEDICINAL 

PRODUCT 



 

13 

A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE 

 

Name and address of the manufacturer(s) responsible for batch release 

 

S.A. Alcon Couvreur N.V. 

Rijksweg 14 

B-2870 Puurs 

Belgium 

 

 

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE 

 

Medicinal product subject to medical prescription. 

 

 

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING 

AUTHORISATION 

 

 Periodic Safety Update Reports 

 

The requirements for submission of periodic safety update reports for this medicinal product are set 

out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of 

Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal. 

 

 

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND 

EFFECTIVE USE OF THE MEDICINAL PRODUCT 

 

 Risk Management Plan (RMP) 

 

The MAH shall perform the required pharmacovigilance activities and interventions detailed in 

the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed 

subsequent updates of the RMP. 

 

An updated RMP should be submitted: 

 At the request of the European Medicines Agency; 

 Whenever the risk management system is modified, especially as the result of new information 

being received that may lead to a significant change to the benefit/risk profile or as the result of 

an important (pharmacovigilance or risk minimisation) milestone being reached. 

 



 

14 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ANNEX III 

 

LABELLING AND PACKAGE LEAFLET 



 

15 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

A. LABELLING 



 

16 

 

PARTICULARS TO APPEAR ON THE OUTER PACKAGING 

 

CARTON FOR SINGLE BOTTLE 4.0 mL + CARTON FOR 3 x 4.0 mL BOTTLES 

 

 

1. NAME OF THE MEDICINAL PRODUCT 

 

IZBA 30 micrograms/mL eye drops, solution 

travoprost 

 

 

2. STATEMENT OF ACTIVE SUBSTANCE 

 

1 mL of solution contains 30 micrograms of travoprost 

 

 

3. LIST OF EXCIPIENTS 

 

Polyquaternium-1, polyoxyethylene hydrogenated castor oil 40 (HCO-40), boric acid, mannitol, 

sodium chloride, propylene glycol, sodium hydroxide and/or hydrochloric acid (to adjust pH) and 

purified water. 

 

See leaflet for further information. 

 

 

4. PHARMACEUTICAL FORM AND CONTENTS 

 

Eye drops, solution 

 

1 bottle of 2.5 mL 

3 bottles of 2.5 mL 

 

 

5. METHOD AND ROUTE OF ADMINISTRATION 

 

Read the package leaflet before use. 

Ocular use 

 

 

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 

OF THE SIGHT AND REACH OF CHILDREN 

 

Keep out of the sight and reach of children. 

 

 

7. OTHER SPECIAL WARNING(S), IF NECESSARY 

 



 

17 

 

8. EXPIRY DATE 

 

EXP 

Discard 4 weeks after first opening. 

Opened: 

Opened (1): 

Opened (2) 

Opened (3) 

 

 

9. SPECIAL STORAGE CONDITIONS 

 

 

10 SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 

OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 

APPROPRIATE 

 

 

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER 

 

Novartis Europharm Limited 

Vista Building 

Elm Park, Merrion Road 

Dublin 4 

Ireland 

 

 

12. MARKETING AUTHORISATION NUMBERS 

 

EU/1/13/905/001 1 x 4.0 mL 

EU/1/13/905/002 3 x 4.0 mL 

 

 

13. BATCH NUMBER 

 

Lot 

 

 

14. GENERAL CLASSIFICATION FOR SUPPLY 

 

 

15. INSTRUCTIONS ON USE 

 

 

16 INFORMATION IN BRAILLE 

 

IZBA 

 



 

18 

 

17. UNIQUE IDENTIFIER – 2D BARCODE 

 

2D barcode carrying the unique identifier included. 

 

 

18. UNIQUE IDENTIFIER – HUMAN READABLE DATA 

 

PC: 

SN: 

NN: 

 



 

19 

 

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS 

 

BOTTLE LABEL 

 

 

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION 

 

IZBA 30 micrograms/mL eye drops 

travoprost 

 

Ocular use. 

 

 

2. METHOD OF ADMINISTRATION 

 

 

3. EXPIRY DATE 

 

EXP 

 

 

4. BATCH NUMBER 

 

Lot 

 

 

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 

 

2.5 mL 

 

 

6. OTHER 

 



 

20 

 

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS 

 

OVERWRAP 

 

 

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION 

 

IZBA 30 micrograms/mL eye drops, solution 

travoprost 

 

 

2. METHOD OF ADMINISTRATION 

 

Read the package leaflet before use. 

 

 

3. EXPIRY DATE 

 

EXP 

Discard 4 weeks after first opening 

 

 

4. BATCH NUMBER 

 

Lot 

 

 

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 

 

2.5 mL 

 

 

6. OTHER 

 



 

21 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

B. PACKAGE LEAFLET 



 

22 

Package leaflet : Information for the user 

 

IZBA 30 micrograms/mL eye drops, solution 

travoprost 

 

Read all of this leaflet carefully before you start using this medicine because it contains 

information important for you 

- Keep this leaflet. You may need to read it again. 
- If you have any further questions, ask your doctor or pharmacist. 
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, 

even if their signs of illness are the same as yours. 

- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side 
effects not listed in this leaflet. See section 4. 

 

What is in this leaflet 

 

1. What IZBA is and what it is used for 

2. What you need to know before you use IZBA 

3. How to use IZBA 

4. Possible side effects 

5. How to store IZBA 

6. Contents of the pack and other information 

 

 

1. What IZBA is and what it is used for 

 

IZBA contains travoprost, one of a group of medicines called prostaglandin analogues. 

IZBA is used to reduce high pressure in the eye in adults, adolescents and children from 3 years 

old onward. This pressure can lead to an illness called glaucoma. 

 

 

2. What you need to know before you use IZBA 

 

Do not use IZBA: 

 if you are allergic to travoprost or any of the other ingredients of this medicine (listed in 
section 6). 

 

Ask your doctor for advice if this applies to you. 

 

Warnings and precautions 

 

 IZBA may increase the length, thickness, colour and/or number of your eyelashes. Changes in 
the eyelids including unusual hair growth or in the tissues around the eye have also been 

observed. 

 

 IZBA may gradually change the colour of your iris (the coloured part of your eye). This 
change may be permanent. 

 

 If you have had cataract surgery talk to your doctor before you use IZBA. IZBA may increase 
the risk of inflammation of the back of the eye. 

 

 If you have current or previous history of an eye inflammation (iritis and uveitis) talk to your 
doctor before you use IZBA. Eye inflammation is a possible side effect which may be 

associated with the use of prostaglandin analogues such as IZBA. 



 

23 

 

 Travoprost may be absorbed through the skin. If any of the medicinal product comes into 
contact with the skin, it should be washed off straight away. This is especially important in 

women who are pregnant or are attempting to become pregnant. 

 

 If you wear soft contact lenses, do not use the drops with your lenses in. After using the drops 
wait 15 minutes before putting your lenses back in. 

 

Talk to your doctor or pharmacist before using IZBA. 

 

Children and adolescents 

 

Use of IZBA is not recommended to those children under 3 years of age. The safety and efficacy of 

travoprost have not been established in this age group. 

 

Other medicines and IZBA 

 

Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines. 

 

Pregnancy and breast-feeding 

 

Do not use IZBA if you are pregnant. The effects of this medicine in pregnant women are not 

known. If you think that you may be pregnant speak with your doctor right away. If you could become 

pregnant you must use adequate contraception whilst you use IZBA. 

 

Do not use IZBA if you are breast-feeding. IZBA may get into your milk. 

 

Driving and using machines 

 

You may find that your vision is blurred for a time just after you use IZBA. Do not drive or use 

machines until this has worn off. 

 

IZBA contains hydrogenated castor oil and propylene glycol which may cause skin reactions and 

irritation. 

 

 

3. How to use IZBA 

 

Always use this medicine exactly as your doctor or the doctor treating your child has told you. You 

should check with your doctor, the doctor treating your child or pharmacist if you are not sure. 

 

The recommended dose is 

 

One drop in the affected eye or eyes, once a day in the evening. 

Only use IZBA in both eyes if your doctor told you to. Use it for as long as your doctor or the doctor 

treating your child told you to. 

IZBA can be used in children from 3 years to <18 years at the same dose as for adults. 

 

IZBA should only be used as an eye drop. 

 

 

 

 

 

 

 

 1 2 3 4 



 

24 

 

 Immediately before using a bottle for the first time, tear open the overwrap pouch, take the 
bottle out (picture 1) and write the date of opening on the carton in the space provided. 

 Wash your hands. 

 Twist off the cap. 

 Hold the bottle, pointing down, between your thumb and fingers. 

 Tilt your head or your child’s head gently back. Pull down the eyelid with a clean finger, until 
there is a ‘pocket’ between the eyelid and the eye. The drop will go in here (picture 2). 

 Bring the bottle tip close to the eye. Use a mirror if it helps. 

 Do not touch the eye or eyelid, surrounding areas or other surfaces with the dropper. It 
could infect the drops. 

 Gently squeeze the bottle to release one drop of IZBA at a time. (picture 3). 

 After using IZBA, keep the eyelid closed, apply gentle pressure by pressing a finger into the 
corner of the eye, by the nose (picture 4) for at least 1 minute. This helps to stop IZBA getting 

into the rest of the body. 

 If you use drops in both eyes, repeat the steps for the other eye. 

 Close the bottle cap firmly immediately after use. 

 Only use one bottle at a time. Do not open the pouch until you need to use the bottle. 
 

If a drop misses your eye, try again. 

 

If you or your child are using other eye preparations such as eye drop or eye ointment, wait for at 

least 5 minutes between putting in IZBA and the other eye preparations. 

 

If you or your child use more IZBA than you should 

Rinse all the medicine out with warm water. Don’t put in any more drops until it’s time for your next 

regular dose. If IZBA is swallowed, consult your doctor or pharmacist immediately. 

 

If you forget to use IZBA 

Continue with the next dose as planned. Do not use a double dose to make up for a forgotten dose. 

Never use more than one drop in the affected eye(s) in a single day. 

 

If you stop using IZBA 

Do not stop using IZBA without first speaking to your doctor or the doctor treating your child, the 

pressure in your eye or your child’s eye will not be controlled which could lead to loss of sight. 

 

If you have any further questions on the use of this medicine, ask your doctor, the doctor treating your 

child or pharmacist. 

 

 

4. Possible side effects 

 

Like all medicines, this medicine can cause side effects although not everybody gets them. 

 

The following side effects have been observed with IZBA: 

 

Very common side effects: may affects more than 1 in 10 people 

 

Effects in the eye: eye redness. 

 

Common side effects: may affect up to 1 in 10 people 

 

Effects in the eye: eye discomfort, itchy eye, and dry eye. 

 



 

25 

Uncommon side effects: may affect up to 1 in 100 people 

 

Effects in the eye: inflammation inside the eye, eye surface inflammation with/out surface damage, 

inflammation of the eyelids, inflammation of the conjunctiva, eye pain, sensitivity to light, blurred or 

abnormal vision, swelling or crusting of eyelids, eye discharge, darkening of skin around the eye(s), 

growth and thickening of the eyelashes. 

 

General side effects: rash or itching of the skin. 

 

In addition, the following side effects have been observed with another medicine containing a 

higher strength of travoprost (40 micrograms/mL): 

 

Very common side effects: may affects more than 1 in 10 people 

 

Effects in the eye: eye redness. 

 

Common side effects: may affect up to 1 in 10 people 

 

Effects in the eye: changes in the colour of the iris (coloured part of the eye), eye irritation. eye pain, 

eye discomfort, dry eye, itchy eye. 

 

Uncommon side effects: may affect up to 1 in 100 people 

 

Effects in the eye: corneal disorder, eye inflammation, iris inflammation, inflammation inside the eye, 

eye surface inflammation with/out surface damage, sensitivity to light, eye discharge, eyelid 

inflammation, eyelid redness, swelling around the eye, eyelid itching, blurred vision, increased tear 

production, infection or inflammation of the conjunctiva (conjunctivitis), abnormal turning outward of 

the lower eyelid, clouding of the eye, eyelid crusting, growth of eyelashes. 

 

General side effects: increased allergic symptoms, headache, irregular heart beat, cough, stuffy nose, 

throat irritation, darkening of skin around the eye (s), skin darkening, abnormal hair texture, excessive 

hair growth. 

 

Rare: may affect up to 1 in 1,000 people 

 

Effects in the eye: perception of flashing lights, eczema of the eyelids, abnormally positioned 

eyelashes that grow back toward the eye, eye swelling, reduced vision, halo vision, decreased eye 

sensation, inflammation of the glands of the eyelids, pigmentation inside the eye, increase in pupil 

size, eyelash thickening, change in eyelash colour, tired eyes. 

 

General side effects: eye viral infection, dizziness, bad taste, irregular or decreased heart rate, 

increased or decreased blood pressure, shortness of breath, asthma, nasal allergy or inflammation, 

nasal dryness, voice changes, gastrointestinal discomfort or ulcer, constipation, dry mouth, redness or 

itching of the skin, rash, hair colour change, loss of eyelashes, joint pain, musculoskeletal pain, 

generalised weakness. 

 

Not known: frequency cannot be estimated from the available data 

 

Effects in the eye: inflammation of the back of the eye, eyes appear more inset. 

 

General side effects: depression, anxiety, insomnia, sensation of false movement, ringing in ears, chest 

pain, abnormal heart rhythm, increased heart beat, worsening of asthma, diarrhoea, nose bleeds, 

abdominal pain, nausea, vomiting, itching, abnormal hair growth, painful or involuntary urination, 

increase in prostate cancer marker. 



 

26 

 

In children and adolescents, the most common side effects seen with the medicine containing a higher 

strength of travoprost (40 micrograms/mL) are eye redness and growth of eyelashes. Both side effects 

were observed with a higher incidence in children and adolescents compared to adults. 

 

Reporting of side effects 

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 

not listed in this leaflet. You can also report side effects directly via the national reporting system 

listed in Appendix V. By reporting side effects you can help provide more information on the safety of 

this medicine. 

 

 

5. How to store IZBA 

 

Keep this medicine out of the sight and reach of children. 

 

Do not use this medicine after the expiry date which is stated on the bottle and the box after ‘EXP’. 

The expiry date refers to the last day of the month. 

 

This medicine does not require any special storage conditions. 

 

You must throw away the bottle 4 weeks after you first opened it, to prevent infections, and use a 

new bottle. Write down the date you opened it in the space on each carton box. 

 

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 

throw away medicines you no longer used. These measures will help protect the environment. 

 

 

6. Contents of the pack and other information 

 

What IZBA contains 

- The active substance is travoprost. Each mL of solution contains 30 micrograms of travoprost. 
- The other ingredients are: polyquaternium-1, polyoxyethylene hydrogenated castor oil 40, 

propylene glycol (see end of section 2), sodium chloride, boric acid, mannitol and purified 

water. Tiny amounts of hydrochloric acid or sodium hydroxide are added to keep acidity levels 

(pH levels) normal. 

 

What IZBA looks like and contents of the pack 

IZBA eye drop is a liquid (a clear, colourless solution) supplied in a 4 mL plastic bottle with a screw 

cap. Each bottle contains 2.5 mL of travoprost eye drops and each bottle is placed in a pouch. 

 

Pack sizes: 1 or 3 bottles. 

 

Not all pack sizes may be marketed. 

 

Marketing Authorisation Holder 

Novartis Europharm Limited 

Vista Building 

Elm Park, Merrion Road 

Dublin 4 

Ireland 

 

Manufacturer 

S.A. Alcon Couvreur N.V. 

Rijksweg 14 

B-2870 Puurs 

Belgium 

http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc


 

27 

 

For any information about this medicine, please contact the local representative of the Marketing 

Authorisation Holder: 

 

België/Belgique/Belgien 

Novartis Pharma N.V. 

Tél/Tel: +32 2 246 16 11 

 

Lietuva 

SIA “Novartis Baltics” Lietuvos filialas 

Tel: +370 5 269 16 50 

България 

Novartis Bulgaria EOOD 

Тел.: +359 2 489 98 28 

 

Luxembourg/Luxemburg 

Novartis Pharma N.V. 

Tél/Tel: +32 2 246 16 11 

 

Česká republika 

Novartis s.r.o. 

Tel: +420 225 775 111 

Magyarország 

Novartis Hungária Kft. 

Tel.: +36 1 457 65 00 

Danmark 

Novartis Healthcare A/S 

Tlf: +45 39 16 84 00 

 

Malta 

Novartis Pharma Services Inc. 

Tel: +356 2122 2872 

Deutschland 

Novartis Pharma GmbH 

Tel: +49 911 273 0 

Nederland 

Novartis Pharma B.V. 

Tel: +31 26 37 82 111 

 

Eesti 

SIA Novartis Baltics Eesti filiaal 

Tel: +372 66 30 810 

 

Norge 

Novartis Norge AS 

Tlf: +47 23 05 20 00 

Ελλάδα 

Novartis (Hellas) A.E.B.E. 

Τηλ: +30 210 281 17 12 

 

Österreich 

Novartis Pharma GmbH 

Tel: +43 1 86 6570 

España 

Novartis Farmacéutica, S.A. 

Tel: +34 93 306 42 00 

Polska 

Novartis Poland Sp. z o.o. 

Tel.: +48 22 375 4888 

 

France 

Novartis Pharma S.A.S. 

Tél: +33 1 55 47 66 00 

Portugal 

Novartis Farma - Produtos Farmacêuticos, S.A. 

Tel: +351 21 000 8600 

 

Hrvatska 

Novartis Hrvatska d.o.o. 

Tel. +385 1 6274 220 

România 

Novartis Pharma Services Romania SRL 

Tel: +40 21 31299 01 

 

Ireland 

Novartis Ireland Limited 

Tel: +353 1 260 12 55 

Slovenija 

Novartis Pharma Services Inc. 

Tel: +386 1 300 75 50 

 

Ísland 

Vistor hf. 

Sími: +354 535 7000 

Slovenská republika 

Novartis Slovakia s.r.o. 

Tel: + 421 2 5542 5439 

 

Italia 

Novartis Farma S.p.A. 

Tel: +39 02 96 54 1 

 

 

Suomi/Finland 

Novartis Finland Oy 

Puh/Tel: +358 (0)10 6133 200 



 

28 

Κύπρος 

Novartis Pharma Services Inc. 

Τηλ: +357 22 690 690 

 

Sverige 

Novartis Sverige AB 

Tel: +46 8 732 32 00 

Latvija 

SIA “Novartis Baltics” 

Tel: +371 67 887 070 

 

United Kingdom 

Novartis Pharmaceuticals UK Ltd. 

Tel: +44 1276 698370 

 

This leaflet was last revised in 

 

 

Other sources of information 

Detailed information on this medicine is available on the European Medicines Agency web site: 

http://www.ema.europa.eu. 

 

http://www.ema.europa.eu/

	SUMMARY OF PRODUCT CHARACTERISTICS
	A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE
	B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
	C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
	D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
	A. LABELLING
	B. PACKAGE LEAFLET